Loxcip-LP Eye Drop is a combination ophthalmic solution containing Loteprednol etabonate 0.5% w/v, a corticosteroid with potent anti-inflammatory properties, and Moxifloxacin 0.5% w/v, a broad-spectrum fluoroquinolone antibiotic. This formulation is indicated for the treatment of ocular inflammatory conditions accompanied by bacterial infections or at risk of secondary bacterial contamination. Loteprednol etabonate acts by inhibiting multiple inflammatory mediators, thereby reducing ocular inflammation, edema, and discomfort, while Moxifloxacin effectively inhibits bacterial DNA gyrase and topoisomerase IV, leading to bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens. Loxcip-LP Eye Drop is commonly prescribed for postoperative inflammation following ocular surgery, bacterial conjunctivitis, and other inflammatory eye disorders with suspected or confirmed bacterial involvement. The combination therapy offers the advantage of simultaneous anti-inflammatory and antimicrobial effects, improving patient compliance and therapeutic outcomes. It should be used under ophthalmologic supervision, with caution in patients with known hypersensitivity to corticosteroids or fluoroquinolones. Prolonged use may increase the risk of ocular hypertension, cataract formation, or secondary infections. Patients should adhere to prescribed dosage and report any adverse reactions promptly to their healthcare provider.